Drug Type Small molecule drug |
Synonyms- |
Target |
Action stimulants |
Mechanism Akt stimulants(Proto-oncogene proteins c-akt stimulants), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants), PI3K family stimulants(Phosphatidylinositol 3-kinase family stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H12O6 |
InChIKeyMBNGWHIJMBWFHU-UHFFFAOYSA-N |
CAS Registry520-34-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Preclinical | India | 21 Oct 2025 | |
| Thromboembolism | Preclinical | China | 20 Mar 2025 | |
| Thrombosis | Preclinical | China | 20 Mar 2025 | |
| Liver Injury | Preclinical | China | 01 Mar 2025 | |
| Liver Injury | Preclinical | China | 01 Mar 2025 | |
| Toxic effect of aflatoxin | Preclinical | China | 01 Mar 2025 | |
| Toxic effect of aflatoxin | Preclinical | China | 01 Mar 2025 |





